Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM ...

Beam Therapeutics (NASDAQ:BEAM) executives and clinical collaborators presented updated top-line data from the company’s ...

This study investigates the association between liver fibrosis and diabetic peripheral neuropathy (DPN) in patients with type ...

Non-alcoholic fatty liver disease is on the rise and mainly stems from metabolic dysfunction. Dr Sood shares five facts about ...

The Fibrosis-4 (FIB-4) index, computed from age, aspartate aminotrasfertase (AST) and alanine aminotransferase (ALT) levels, and platelet count, was originally developed in 832 pa ...

During the holy month of Ramadan, a viral video warns of hidden fungi and contamination risks in dates, but what does ...

Barclays 28th Annual Global Healthcare Conference March 12, 2026 11:30 AM EDTCompany ParticipantsAlexander Cumbo - ...

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting(OXFORDSHIRE, England & ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned ...

Is your liver health in danger? Scroll down to know what liver damage feels and looks like and what signs the body sends when ...

In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 ...

FIB-4 index shows limited accuracy for individual MASLD patients. Learn more about its role and challenges in liver fibrosis ...